To demonstrate the prophylactic effect of calcium sulfate beads loaded with antibiotic in patients with non-modifiable risk factors that will undergo a hip or knee joint replacement, comparing with a control group.
To know the economic cost generated in antibiotic prophylaxis with calcium sulfate beads in patients undergoing hip or knee joint replacement with non-modifiable risk factors.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infection | Device: Antibiotic local prophylaxis with medicated calcium sulfate beads Procedure: Classical parenteral antibiotic prophylaxis | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 87 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Randomised controlled trial. Study participants are randomly assigned to one of two groups: the experimental group receiving the Calcium sulfate beds with antibiotics and a comparison group (control) which receives a conventional prophylactic therapy. |
Masking: | Single (Participant) |
Masking Description: | No participant will know during the study in which group will be assigned. |
Primary Purpose: | Prevention |
Official Title: | Application of Antibiotic Loaded Calcium Sulfate as Prophylaxis for Patients With Non Modifiable Risk Factors for Periprosthetic Joint Infections |
Actual Study Start Date : | May 22, 2019 |
Actual Primary Completion Date : | April 22, 2020 |
Actual Study Completion Date : | July 15, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Calcium sulfate Group
Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement
|
Device: Antibiotic local prophylaxis with medicated calcium sulfate beads
Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
Other Name: Hip or Knee Joint Replacement
|
Active Comparator: Control Group
Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement
|
Procedure: Classical parenteral antibiotic prophylaxis
Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
Other Name: Hip pr Knee Joint Replacement
|
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Mexico | |
HOSPITAL REGIONAL TLALNEPANTLA ISSEMyM | |
Tlalnepantla, Mexico, 54090 |
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | May 29, 2019 | ||||||
First Posted Date ICMJE | June 6, 2019 | ||||||
Results First Submitted Date ICMJE | July 19, 2020 | ||||||
Results First Posted Date ICMJE | August 18, 2020 | ||||||
Last Update Posted Date | August 20, 2020 | ||||||
Actual Study Start Date ICMJE | May 22, 2019 | ||||||
Actual Primary Completion Date | April 22, 2020 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Partipants Achieving a Lower Hip or Knee Periprosthetic Joint Infection Rate With Local Versus Conventional Intravenous Antibiotic Prophilaxys, Measured With CRP, ERS in Serum and Sinovial Fluid Leukocytes , Over the 12-week Observation Period. [ Time Frame: Day 5, Weeks 4, 8, and 12 ] Acute periprosthetic knee or hip infection was determined using CRP and ESR serum biomarkers, which are the most commonly published serum biomarkers in periprosthetic joint infection literature. The cut off point for CRP was considered 93mg/L and 44mm/hr for ESR. The serum biomarker sample was taken and evaluated on day 5 and weeks 4, 8 and 12. Leukocytes in synovial fluid are among the criteria for definition of periprosthetic joint infection with a cut off point above 12,800 cells/µL and were only included if serum biomarkers were elevated.
|
||||||
Original Primary Outcome Measures ICMJE |
To compare local against conventional intravenous prophylaxis in peri-prosthetic hip or knee infection of patients with non- modifiable risk factors. [ Time Frame: 3 months ] • To compare the prevalence of peri-prosthetic hip or knee infection with antibiotic prophylaxis between control (intravenous) versus study group (local with calcium sulfate beads). Intravenous prophylaxis group (control) will use 1 gr of ceftriaxone 30 minutes before surgery and study group will use prophylaxis by calcium sulfate beads loaded with 3 gr of vancomycin in the transoperative procedure, as interface between the acetabulum and the metal cup and between the femoral canal and the porous stem in the hip; for the knee, calcium sulfate beads will be applied in the femoral and tibial canal and in the soft ridged tissue. Using the data collection sheet, investigators will fill-in variables to determine acute peri-prosthetic infection using CRP, ESR and Leucocytes in synovial fluid in the next 5 days, 4, 6, 8 and 12 weeks. Once all the results have been obtained, a statistic analysis will be carried out using T student and measure of central tendency statistics.
|
||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
Length of Stay as an Indicator of the Hospital Economic Burden [ Time Frame: Surgical procedure day to hospital discharge. ] The length of stay is an important indicator of efficiency and hospital economic burden. The reduction in number of hospitalization days results in lower risk of infection and less medication side effects and decreased need of hospital supplies. The difference in the average days of hospitalization between both groups indirectly represents the economic cost spent by the hospital.
|
||||||
Original Secondary Outcome Measures ICMJE |
Establish differences in the cost benefit of prophylaxis with or without calcium sulfate beads. [ Time Frame: 3 months ] The control and study groups will be analyzed with ANOVA test for differences in economics criteria: costs for time in the operating room, hospital stay, outpatient visits and additional procedures. Statistical analysis of both groups will be carried out. Any statistically meaningful differences will be used to calculate potential health economic benefits of the experimental group, based upon information on standard costs.
|
||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors. | ||||||
Official Title ICMJE | Application of Antibiotic Loaded Calcium Sulfate as Prophylaxis for Patients With Non Modifiable Risk Factors for Periprosthetic Joint Infections | ||||||
Brief Summary |
To demonstrate the prophylactic effect of calcium sulfate beads loaded with antibiotic in patients with non-modifiable risk factors that will undergo a hip or knee joint replacement, comparing with a control group. To know the economic cost generated in antibiotic prophylaxis with calcium sulfate beads in patients undergoing hip or knee joint replacement with non-modifiable risk factors. |
||||||
Detailed Description | Since joint replacement procedures have been successful in recent decades, every year the number of implanted prostheses is increasing, however, at the same time, orthopaedic surgeons also find complications inherent to this surgery, where peri-prosthetic infection results to be the most devastating. In order to find a solution to this terrible complication, prophylactic and therapeutic measures have been implemented, emerging techniques where the application of local antibiotics in the surgical site has turned out to be a promising concept. It has been shown that the non-modifiable risk factors of patients undergoing joint replacement surgery increase the risk of infection rate. Therefore, the identification of risk factors, decolonization and the prophylactic administration of antibiotics allow an effective reduction of periprosthetic infection. In order to reduce and, as far as posible, avoid periprosthetic infections in participants undergo knee or hip joint replacement with non-modifiable risk factors, the prophylactic use of calcium sulphate loaded with antibiotic for local application is proposed. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 4 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Randomised controlled trial. Study participants are randomly assigned to one of two groups: the experimental group receiving the Calcium sulfate beds with antibiotics and a comparison group (control) which receives a conventional prophylactic therapy. Masking: Single (Participant)Masking Description: No participant will know during the study in which group will be assigned. Primary Purpose: Prevention
|
||||||
Condition ICMJE | Infection | ||||||
Intervention ICMJE |
|
||||||
Study Arms ICMJE |
|
||||||
Publications * |
|
||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE |
87 | ||||||
Original Estimated Enrollment ICMJE |
80 | ||||||
Actual Study Completion Date ICMJE | July 15, 2020 | ||||||
Actual Primary Completion Date | April 22, 2020 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 60 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Mexico | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03976466 | ||||||
Other Study ID Numbers ICMJE | 01 | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||
Responsible Party | Julio Carlos Velez de Lachica, Hospital Regional Tlalnepantla | ||||||
Study Sponsor ICMJE | Hospital Regional Tlalnepantla | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE | Not Provided | ||||||
PRS Account | Hospital Regional Tlalnepantla | ||||||
Verification Date | August 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |